Analyzing vitreous fluid to identify biomarkers in retinal diseases
Nuclear Magnetic Resonance (NMR)-Based Metabolomic Characterisation of Vitreoretinal Diseases Using Vitreous Fluid
This study is trying to find specific markers in the eye fluid of people with different retinal diseases to help understand these conditions better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 450 (estimated) |
| Ages | 40 Years to 90 Years |
| Sex | All |
| Sponsor | Renmin Hospital of Wuhan University Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT06429969 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the metabolomic profiles of various vitreoretinal diseases using nuclear magnetic resonance (NMR) analysis of vitreous fluid. Participants diagnosed with conditions such as idiopathic macular hole, diabetic retinopathy, retinal detachment, idiopathic macular epiretinal membrane, and retinal vein occlusion, who require pars plana vitrectomy, will have their vitreous samples collected for analysis. The study will categorize participants into groups based on their specific diagnoses and compare metabolomic differences to identify potential biomarkers for these diseases. No interventions will be performed, as the study focuses solely on preoperative data collection and analysis of leftover vitreous fluid.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with vitreoretinal diseases who require pars plana vitrectomy.
Not a fit: Patients with vitreoretinal diseases that do not require surgery or those with a history of previous vitrectomy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the identification of biomarkers that improve the prevention, early diagnosis, and treatment of vitreoretinal diseases.
How similar studies have performed: While the approach of using metabolomics in vitreous fluid analysis is relatively novel, similar studies in other areas have shown promise in identifying biomarkers for various diseases.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Confirmation of IMH diagnosis with concomitant need for PPV surgery; 2. Confirmation of DR diagnosis with concomitant need for PPV surgery; 3. Confirmation of RD diagnosis with concomitant need for PPV surgery; 4. Confirmation of IMM diagnosis with concomitant need for PPV surgery; 5. Confirmation of RVO diagnosis with concomitant need for PPV surgery. Exclusion Criteria: 1. Diagnosed vitreoretinal disease with no need for PPV surgery; 2. Previous history of PPV surgery; 3. Combination of other active ophthalmic diseases, such as acute conjunctivitis and uveitis; 4. Combination of serious systemic diseases such as hypertension and diabetes mellitus.
Where this trial is running
Wuhan, Hubei
- Eye, Center, Renmin Hospital of Wuhan University — Wuhan, Hubei, China (Recruiting)
Study contacts
- Principal investigator: Lei Du — Renmin Hospital of Wuhan University
- Study coordinator: Liwei Cheng
- Email: wdrmiit@163.com
- Phone: 027-88041911
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.